Coexistence of JAK2V617F and CALR mutation in Tunisian cohort with Philadelphia-negative chronic myeloproliferative neoplasms

Coexistence of JAK2V617F and CALR mutation in Tunisian cohort with Philadelphia-negative chronic myeloproliferative neoplasms

Bibliographic Details
Main Authors:	Hejer Elmahmoudi, Jbali Chourouk, Elborgi Wejden, Ghali Ons, Zahra Kouther, Gouider Emna
Format:	Article
Language:	English
Published:	Elsevier 2023-01-01
Series:	Journal of Taibah University Medical Sciences
Online Access:	http://www.sciencedirect.com/science/article/pii/S1658361223001762

Similar Items

Multiplex-PCR is a useful and economical method to detect large exon deletions in severe hemophilia A in developing countries: Experience of Tunisia
by: Hejer Elmahmoudi, et al.
Published: (2023-01-01)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
by: İpek Yonal Hindilerden, et al.
Published: (2023-08-01)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
by: Kathrin Olschok, et al.
Published: (2023-10-01)

Bleeding phenotype in hemophilia carriers : Tunisian center experience
by: Ons Ghali, et al.
Published: (2023-01-01)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
by: Kathrin Olschok, et al.
Published: (2023-08-01)

Evaluation of the JAK2V617F mutational burden in patients with philadelphia chromosome negative myeloproliferative neoplasms: A single-center experience
by: Popova-Labachevska M, et al.
Published: (2019-12-01)

The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
by: M. Cem Ar, et al.
Published: (2012-08-01)

The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms
by: Tanja Belčič Mikič, et al.
Published: (2021-03-01)

JAK2-V617F Mutation and Philadelphia Positive Chronic Myeloid Leukemia
by: Fatemeh Nadali, et al.
Published: (2009-10-01)

JAK2-V617F Mutation and Philadelphia Positive Chronic Myeloid Leukemia
by: Fatemeh Nadali, et al.
Published: (2009-12-01)

Inhibitor in people living with hemophilia B severe : A four cases report
by: Ghali Ons, et al.
Published: (2023-01-01)

Inhibitor in Von Willebrand disease: Two case reports
by: Ghali Ons, et al.
Published: (2023-01-01)

Low <i>JAK2</i> V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional <i>CALR</i> or <i>MPL</i> Gene Mutations
by: Tatiana V. Makarik, et al.
Published: (2021-04-01)

Development of paroxysmal nocturnal hemoglobinuria in CALR-positive myeloproliferative neoplasm
by: Fraiman YS, et al.
Published: (2016-05-01)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
by: Sophie Allain-Maillet, et al.
Published: (2020-08-01)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
by: Alexandre Guy, et al.
Published: (2020-06-01)

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms
by: Panhong Gou, et al.
Published: (2024-01-01)

Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance
by: Saeid Shahrabi, et al.
Published: (2018-10-01)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
by: Shirin Ferdowsi, et al.
Published: (2016-04-01)

Von Willebrand Disease laboratory diagnosis in a low middle income country
by: O.N.S. GHALI, et al.
Published: (2023-01-01)

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
by: Kristin Holl, et al.
Published: (2024-02-01)

P1046: SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
by: W. Novak, et al.
Published: (2022-06-01)

The JAK2V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
by: Lai Yee Orbell, et al.
Published: (2023-11-01)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
by: Fani Kalala, et al.
Published: (2012-06-01)

Effects of <i>CALR</i>-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms
by: Hyun-Young Kim, et al.
Published: (2022-10-01)

Comparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders
by: L. A. Kesaeva, et al.
Published: (2019-07-01)

P1045: IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS?
by: E. Morsia, et al.
Published: (2022-06-01)

P1009: SKLB054, A NOVEL JAK2 INHIBITOR, POTENTLY TREATS MYELOPROLIFERATIVE NEOPLASM WITH JAK2V617F MUTATION
by: Ailin Zhao, et al.
Published: (2023-08-01)

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
by: Bench, A, et al.
Published: (2013)

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations
by: Bench, A, et al.
Published: (2013)

Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report
by: A, Alia Suzana, et al.
Published: (2023)

PB2193: JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS
by: Xuefei MA, et al.
Published: (2023-08-01)

Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms
by: Panhong Gou, et al.
Published: (2022-01-01)

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients
by: Zehra Narlı Özdemir, et al.
Published: (2024-03-01)

Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
by: Li Huo, et al.
Published: (2023-01-01)

Application of heteroduplex analysis for CALR mutation screening detection in patients with Ph-myeloproliferative neoplasms
by: T. N. Subbotina, et al.
Published: (2021-06-01)

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report
by: Farhad Shaveisi Zadeh, et al.
Published: (2011-04-01)

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report
by: Mehrdad Payande, et al.
Published: (2011-06-01)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
by: Federico Lussana, et al.
Published: (2017-02-01)

Applications of Artificial Intelligence in Philadelphia-Negative Myeloproliferative Neoplasms
by: Basel Elsayed, et al.
Published: (2023-03-01)